These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28074989)

  • 1. [Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence].
    Irarrázaval O ME; Gaete G L
    Rev Med Chil; 2016 Oct; 144(10):1326-1335. PubMed ID: 28074989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antagonism of tamoxifen and antidepressants among women with breast cancer].
    Irarrázaval O ME
    Rev Med Chil; 2011 Jan; 139(1):89-99. PubMed ID: 21526323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
    Desmarais JE; Looper KJ
    J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
    Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
    Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
    Binkhorst L; Bannink M; de Bruijn P; Ruit J; Droogendijk H; van Alphen RJ; den Boer TD; Lam MH; Jager A; van Gelder T; Mathijssen RH
    Clin Pharmacokinet; 2016 Feb; 55(2):249-55. PubMed ID: 26446141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.
    Dusetzina SB; Alexander GC; Freedman RA; Huskamp HA; Keating NL
    Breast Cancer Res Treat; 2013 Jan; 137(1):285-96. PubMed ID: 23149465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coprescription of tamoxifen and medications that inhibit CYP2D6.
    Sideras K; Ingle JN; Ames MM; Loprinzi CL; Mrazek DP; Black JL; Weinshilboum RM; Hawse JR; Spelsberg TC; Goetz MP
    J Clin Oncol; 2010 Jun; 28(16):2768-76. PubMed ID: 20439629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
    Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
    Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of endocrine therapy for breast cancer.
    Higgins MJ; Stearns V
    Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.